Efficacy and safety of CagriSema & Retatrutide, CGM benefits beyond T2D, & more!

About this episode

This episode reviews the latest research on diabetes treatments and monitoring technologies.

Welcome to the latest episode (July 2026) of DOC Updates , where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Updates : Aroda V, Buzzetti R, Dalskov S et al. " Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study ." The Lancet Diabetes & Endocrinology, 2026; 0 doi: 10.1016/S2213-8587(26)00126-9 Bajaj H, Welch M, Shah P et al. " Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial ." The Lancet, 2026; 407, 2402-2413 doi: 10.1016/S0140-6736(26)00967-0 Melville, N. " CGM Monitoring Benefits Extend to Non-Insulin-Using T2D ." Medscape, June 07, 2026 Aronne, L.J., Horn, D.B., le Roux, C.W. et al. " Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial ." Nat Med(2026) doi…

People in this episode

Hosts: Neil Skolnik, John Russell

Topics covered

• CagriSema
• Retatrutide
• CGM benefits
• type 2 diabetes
• obesity
• cardiometabolic disease

Keywords

• CagriSema
• Retatrutide
• CGM
• type 2 diabetes
• obesity
• cardiometabolic disease
• metformin
• lifestyle interventions

Mentioned in this episode

Organizations: American Diabetes Association

Books & works: Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study, Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial, CGM Monitoring Benefits Extend to Non-Insulin-Using T2D, Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial, Lifestyle and Metformin Interventions and Risk of Multimorbidity in Adults With Prediabetes

More episodes of DOC Updates

• Special Edition: Hypertension Part 2—Advanced Hypertension Management: Uncontrolled and Resistant Hypertension and the Importance of Aldosterone · September 8, 2026 · 40 min
• Special Edition: Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH) · September 3, 2026 · 23 min
• Special Edition: Evidence-Based Strategies for Weight Loss and Long-Term Weight Maintenance · August 24, 2026 · 32 min
• Special Edition: What's Next—The Role of Health Systems in Managing CKD Associated with T1D & T2D · August 17, 2026 · 33 min
• Katherine Tuttle on SGLT2s & CKD in T2D, Alexander Turchin on medications after Metformin, and High vs. Low CVD Risk, the ADA's statement on employment and diabetes, and more! · August 10, 2026 · 36 min
• Impact of Finerenone on Albuminuria in T1D, National Trends in Out-of-Pocket Cost for Glucose-Lowering Drugs, and more! · August 10, 2026 · 32 min